{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.7"},{"groupId":"OG001","value":"81.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1950"},{"groupId":"OG001","value":"1953"}],"units":"Participants"}],"description":"Percentage of patients free from DFS events. DFS events include local, regional, or distant recurrence, second primary cancer or death from any cause prior to recurrence or second primary cancer.","groups":[{"description":"Patients receive oral letrozole once daily for up to 5 years.\n\nLetrozole: Letrozole 2.5 mg taken orally once daily for 5 years","id":"OG000","title":"Group 2 Letrozole"},{"description":"Patients receive oral placebo once daily for up to 5 years.\n\nPlacebo: Placebo tablet taken orally once daily for 5 years","id":"OG001","title":"Group 1 Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"7 years.","title":"Disease-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of patients free of disease"}